Applied Genetic Technologies logo

AGTC - Applied Genetic Technologies News Story

$3.99 -0.1  -1.2%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £123.1m
Enterprise Value £91.8m
Revenue £n/a
Position in Universe 4672nd / 6850

AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021

Tue 16th February, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210216:nGNX1142h7&default-theme=true


-AGTC executives will address critical success factors in gene therapy
manufacturing and the value of the patient perspective in gene therapy
development ----

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) --
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
company conducting human clinical trials of adeno-associated virus (AAV)-based
gene therapies for the treatment of rare diseases, today announced that Dave
Knop, Vice President of Process Development, and Jill Dolgin, PharmD,
Executive Director of Patient Advocacy, will present at the 4th Annual Gene
Therapy for Rare Disorders digital event taking place February 22-25, 2021.

Dr. Knop will lead a pre-conference workshop, “Unifying Process & Analytical
Development to Establish Robust, Scalable Gene Therapy Manufacturing
Processes” on Monday, February 22 from 1:00 – 4:00 PM EST.

“With an increasing number of gene therapies moving toward approval,
manufacturing continues to be a critical component of success with respect to
safety, regulatory approval and commercial viability,” said Dr. Knop. “The
goal of the workshop is to share insights into the configuration of scalable
gene therapy processes designed to pre-emptively overcome challenges to
manufacturing for commercial markets.”

Dr. Dolgin will join a panel of patient advocacy experts, “Channeling
Patient Input: Industry & Patient Advocacy Perspectives” at 3:30 PM EST on
Wednesday, February 24.

“Engagement with patients and caregivers is a critical success factor in
enhancing our understanding of retinal disorders, guiding clinical trial
design, and inspiring our patient-centric culture,” said Dr. Dolgin, “I
look forward to joining the other panel members to discuss our perspectives
and what we can do to address the issues that are meaningful to patients as we
develop and advance our product-development initiatives.”

To learn more about the event and registration, please visit:
https://genetherapy-conference.com/.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and constructing all
critical gene therapy elements and bringing them together to develop
customized therapies that address real patient needs. AGTC’s most advanced
clinical programs leverage its best-in-class technology platform to
potentially improve vision for patients with an inherited retinal disease.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical programs build on the
Company’s industry-leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates to address
substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR Contacts:
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/542616ce-01ae-469d-b4ff-5285f7e0584e)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.